ORDER A TEST Log In Contact Us

TARGET IDENTIFICATION & VALIDATION

Tempus Loop

A proprietary platform that integrates real-world data (RWD), patient-derived organoids (PDOs), and AI/ML to rapidly uncover and help validate actionable targets for oncology R&D.

Accelerate preclinical development

By integrating experimental and computational platforms, Tempus Loop helps overcome critical target ID and validation challenges, which can advance personalized cancer therapeutics.

  • Mitigate translational risk and help improve analytical power by leveraging connected, de-identified real-world patient molecular and clinical data, including outcomes
  • Gather information about resistance mechanisms, pathway alterations, and related gene mutations with a comprehensive systems biology approach
  • Help to expedite timelines with seamless handoffs between integrated wet- and dry-lab workflows
  • Improve confidence in development strategies by validating targets with PDOs and contextualizing insights within RWD
image description
  • Characterize Unmet Needs
    Characterize Unmet Needs

    Analyze multimodal RWD to identify clusters of patients with varying responses and outcomes to standard-of-care treatment.

  • Identify Novel Targets
    Identify Novel Targets

    Leverage multigene signatures, gene network mapping and systems biology approaches to help identify genes and pathways driving disease as potential targets.

  • Validate Targets
    Validate Targets

    Map clusters identified in RWD to relevant PDOs and perform high-throughput CRISPR knockdown screens to help validate novel targets.

How It Works

Two integrated solutions—one AI-powered platform

  1. image description

    Select a target indication (e.g. NSCLC) and identify patient clusters of interest.

  2. image description

    Leverage AI/ML-powered analytics and systems biology approaches to map networks and pathways, and generate an initial target list for validation.

  3. image description

    Map clusters and gene signatures onto relevant patient-derived organoid models, and perform high-throughput CRISPR knockdown screens with identified hits to surface gene signatures with therapeutic potential.

  4. image description

    Loop back to multimodal RWD to perform additional characterization of screen hits, and produce a final target list for further development.

Trusted by hundreds of biopharma to power drug development

EXPLORE LIFE SCIENCES SOLUTIONS

This is AI-enabled precision medicine

This is the future of healthcare.